KRAS and mucinous neoplasm: Neither age, gender, liver metastases, synchronous or metachronous metastasis, PCI ≥ 20, TN-stage, primary tumour location, mucinous tumors, grade of differentiation, whether adjuvant treatment had been given, nor the presence of KRAS or BRAF mutations were significantly associated with lead time from diagnosis of peritoneal metastases to surgery.